EXEL

64.6551.78%
JA

Julie Anne Smith

Independent Director

Ms. Julie Anne Smith is CEO & Director of Juvena Therapeutics, Inc. from August 2026. She served as CEO & Director of Nuvig Therapeutics, Inc. since January 2023 until February 2025. She has been Independent Director of Stoke Therapeutics, Inc. since June 2020. Ms. Smith served as President and Chief Executive Officer of Nuredis, Inc. from August 2017 to July 2018 and also served as its Director. Ms. Smith served as President and Chief Executive Officer at E-scape Bio, Inc. since August 2018. She served as Secretary at E-Scape Bio, Inc. and also served as its Director since August 2018 until 2022. Ms. Smith served as the Chief Executive Officer and President of Raptor Pharmaceuticals Corp. from September 2012 to October 25, 2016. Ms. Smith served as the Chief Operating Officer and Executive Vice President of Strategy at Raptor Pharmaceuticals Corp. since September 10, 2012. She served as Chief Operations Officer of Raptor Therapeutics of Raptor Pharmaceuticals Corp., which she joined in September 2012. She served as the Chief Commercial Officer and Vice President of Alexion Montréal Corp. since September 22, 2008. Ms. Smith served as Vice President of Marketing and New Product Planning of Jazz Pharmaceuticals Public Limited Company since August 2006, where she led commercial strategy and operations. She has experience in healthcare, served as an Executive at Genzyme Corporation since 2001 as Vice President of Global Marketing and Vice President of Product Strategy and Development. Her responsibilities included leading the worldwide commercialization and planning for Myozyme(R), an enzyme replacement therapy for ultra-orphan Pompe disease. Ms. Smith helped to establish the commercial team at Novazyme Pharmaceuticals, a biotech start-up company specializing in orphan drugs. Ms. Smith served in positions of increasing responsibility at Jazz Pharmaceuticals plc from 2006 to 2008, Genzyme Novazyme from 2001 to 2006 and Novazyme Pharmaceuticals, Inc. from 2000 to 2001. She began her career in the pharmaceutical industry at Bristol-Myers Squibb Company, where she held marketing positions of increasing responsibility in oncology and neurology. She served as a Product Manager and Director of channel strategy & design at Bristol-Myers Squibb. She conducted clinical research at Massachusetts General Hospital in neuroendocrinology. Previously, Ms. Smith held key commercial and strategic leadership positions at Enobia Pharma. From 2008 to 2012, she served as Chief Commercial Officer of Enobia Pharmaceuticals until May 2012. She has been an Independent Director at Exelixis, Inc. since September 22, 2016. She served as an Independent Director of Audentes Therapeutics, Inc. from December 12, 2016 to January 15, 2020. From August 2018 to August 2022, Ms. Smith served as the President and Chief Executive Officer of ESCAPE Bio, Inc. She served as a Director of the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board. She served as a Director of Raptor Pharmaceuticals Corp. since January 1, 2015 until October 25, 2016. She was awarded the President’s Award for Innovation. She was named a “40 Under 40” Executive to Watch by the Boston Business Journal and received the “Pinnacle Award for Emerging Executives” from the Boston Chamber of Commerce. In 2015, the San Francisco Business Times honored her as one of the Bay Area’s Influential Women in Business. Ms. Smith holds a B. S. in Biological and Nutritional Science from Cornell University, Ithaca, New York.

Positions